Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04899908 · ClinicalTrials.gov registry record · Phase 2
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
A Phase 2 study of Breast Cancer and Lung Cancer, sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 134
- Enrollment target
- 2
- Study locations
NCT04899908 is a Phase 2 study of Breast Cancer and Lung Cancer that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 134 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04899908, a Phase 2 study of Breast Cancer and Lung Cancer, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 134 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that are more difficult to control with stereotactic radiation alone.
Conditions Studied
Interventions
- OTHER Placebo
- RADIATION Stereotactic Radiation
- DRUG AGuIX gadolinium-based nanoparticles
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2021-09-15 |
| Est. Completion | 2029-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04899908
The ClinicalTrials.gov registry entry for NCT04899908 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04899908 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04899908 about?
NCT04899908 is a clinical study titled "Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases". The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that are more difficult to control with stereotactic radiation alone.
What is the current status of trial NCT04899908?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 134 participants. The study started on 2021-09-15. Estimated completion is 2029-05.
What conditions does trial NCT04899908 study?
This clinical trial studies the following conditions: Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Brain Metastases.
What interventions are being tested in trial NCT04899908?
The interventions under investigation include: Placebo (OTHER), Stereotactic Radiation (RADIATION), AGuIX gadolinium-based nanoparticles (DRUG).
Who is sponsoring clinical trial NCT04899908?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04899908 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.